FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

Description

This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.

Conditions

Food Allergy

Study Overview

Study Details

Study overview

This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.

The Use of Exhaled Nitric Oxide as a Predictive Marker of Allergic Reactions to Oral Food Challenge and Clinical Response of Omalizumab Treatment in Subjects With Multiple Food Allergies

FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

Condition
Food Allergy
Intervention / Treatment

-

Contacts and Locations

Coral Gables

AAADRS Clinical Research Center, Coral Gables, Florida, United States, 33134

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients must meet the following criteria for study entry:
  • * Able and willing to provide written informed consent from patient and parent or guardian and to comply with the study protocol.
  • * Age 6 years of age or older at Visit 1
  • * Documented history of food allergy to one or more of the following foods based on SPT performed at baseline visit:
  • * peanut
  • * milk
  • * egg
  • * tree nuts (Walnut/Pecan, Cashew/Pistachio, Almond, Hazelnut, Brazil nut)
  • * Patients who meet any of the following criteria will be excluded from study entry:
  • * Diagnosis of asthma requiring maintenance medication, including inhaled steroids, leukotriene modifiers, LABA/ICS, biologics medications (Intermittent asthma \[Step 1\] is allowed and defined according to the 2020 NAEPP guidelines (as 'asthma requiring only prn SABA use) and FEV1 \< 80% of predicted normal.
  • * Diagnosis of nasal polyps, cystic fibrosis or any respiratory condition that will skew normally occurring FeNO levels
  • * FeNO (measured in ppb) is lower than a value expected for the age, height, and gender of the participant or inability to perform respiratory collection maneuver
  • * Systemic steroids, leukotriene modifiers, or nasal steroids for any cause/diagnosis within 4 weeks of baseline
  • * Biologic use, for any diagnosis, within five half-lives of Screening
  • * Antibiotic use, systemic/oral/intramuscular, for any cause/diagnosis within 2 weeks of baseline
  • * Active smoker, cigarette, cigar, vape, recreational, and/or prior 10 pack year history
  • * Participant weight or IgE levels outside of the dosing table for OMA
  • * Known history of anaphylaxis/hypersensitivity to OMA
  • * Any medical condition that is serious or unstable that in the opinion of the PI could confound the study results and/or interfere with subject participation or adherence
  • * Pregnant or breastfeeding, or intending to become pregnant during the study or within 60 days after the last dose of OMA
  • * Women of childbearing potential must have a negative serum pregnancy test result during the screening period

Ages Eligible for Study

6 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

AAADRS Clinical Research Center,

Study Record Dates

2025-12